Click on the links below for more
information concerning Interferon
Click
here for information about Interferon and
combination drug treatments and Alternative
therapies
How to give yourself subcuteneous injections
Useful tips on how to give yourself shots and the best body
location(s) for the injections.
Doctors
Close In on Hepatitis C Suppression, Data Show
Healthier HCV
Patients May Want to Pass Up Combo Therapy
US
report questions early treatment of hepatitis C
FDA
Approves Pegasys Combo for HCV
99
Percent of Roche Pegasys Responders Virus Free Up to Four Years
Later
Report
from 37th Annual meeting of the EASL (European Association for the
Study of the Liver) - April 2002
Assessment of side
effects in patients with chronic hepatitis C receiving combination
therapy
Report
from 35th Annual meeting of the EASL
What to do
when standard therapy fails
The roles
of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone
or in combination with alpha interferons, in the treatment of
chronic hepatitis C
Daily
High-Dose Infergen Treatment Clears Hepatitis C Virus Better than
Standard Dosing
Vertex
Reports VX-497 Phase II Clinical Data for HCV
Anti-Oxidant vitamins
delay anemia in combo treatment
Clinical
Study of Maxamine
Sustained
response to INF rarely achieved with high viral load
HCV-RNA
decrease after three days of daily INF predictive of
response
HCV Therapy
Should Be Individually Tailored
A list
of possible side effects that you may experience on Interferon or
Intron A and Ribavirin combination therapy, compiled from actual
patient experiences
Another
patient tells of their experience with combination therapy
New Warnings
Placed On Rebetron Hepatitis Therapy
Interleukin-12
for HCV
New
Patients Receive Strong Warnings about Potential Risk to Fetus with
Combination Therapy (Rebetron)
PEGASYS -
(PEGylated-40K interferon alfa-2a)
Report from
AASLD Meeting About Rebatron Therapy
Basics of
Interferon Injections, as told by a HCV patient
FDA OKs
Potent Hepatitis C Drug (Rebetron)
New
Hepatitis C Combination Treatment Approved (Rebetron) FDA Warns of
Side Effects -- Overlooks Concerns About Pre-packaged Doses
Interferon
Treatment of Relapsers
Long-Term
Follow-Up of HCV Patients with Sustained Virological Response to
Alpha-Interferon
Effect of
Interferon Therapy on the Development of Liver Cancer in Patients
with Hepatitis C
Clinical
Outcome of HCV in Patients Treated with Interferon: Comparison
Between Responders and Non-Responders
Maintenance
Interferon Benefits
Racial
Differences in Response to Interferon Therapy for HCV
Successful
Delivery Of Interferon Without Injection
Differences Between
Interferon-alpha and -beta for Patients with HCV
Interferon
Therapy and Progression to Liver Cancer in HCV
Consensus
Interferon
ALT
Evaluation Two Months into Therapy Predicts Outcome
Latest
Treatment for HCV May Not Be Best
Interferon
Response in Genotypes 1a and 1b can be Predicted Within 48
Hours
Viral
kinetics can predict early response to alpha-interferon in chronic
hepatitis C
Ribavirin
plus INF Alpha Interferon Dosage -
Reduce or Increase?
Characteristics of
Complete Responders to Interferon
Life
Extension Foundation's Protocol for HCV
Easing the
discomfort of interferon - a patient's perspective
Predictive
Factors of Non-Response to Recombinant Interferon Alfa 2B in
Patients with Chronic Hepatitis C
FDA Clears
New Treatment Option For Hepatitis C Patients
Study looks
at hepatitis drug, depression risk
Late
Reactivation of Chronic HCV After Long-Term Sustained Response to
Interferon Therapy
Retreatment of
Chronic Hepatitis C with Interferon Alpha - Longterm follow-up and
prognostic relevance of HCV genotypes
Interferon
Treatment of HCV with Cirrhosis
Adverse
Effects of Interferon
Permanent
response to Interferon therapy in HCV is preceded by rapid
clearance of HCV-RNA serum
Duration
of HCV infection as a predictor of NonResponse to Interferon
Therapy
2 yrs. vs.
6 months of Interferon Therapy
Short-term
vs. Sustained response to Inferferon - Effect on histology
Breakthrough
and Interferon Dose
Early phase
response to Interferon
Targeted
Therapy for Viral Hepatitis
Cutaneous
necrosis associated with interferon alpha-2b
Management
of asymptomatic HCV carriers with normal ALT levels
Interferon
Side Affects
Spontaneous
clearance of HCV Virus
Trial of
Interferon Beta 1a
Cost
effectiveness study of treatment in patients with chronic Hepatitis
C
Full or
Partial Seroreversion in Patients Infected by HCV
Key Interaction
for Interferon Resistance in Hepatitis C Virus Discovered
More HCV
Patients Have Long-Term Response to Lymphoblastoid Interferon in
Multicenter Trial
Home | What is HCV | Transmission |
Future |
Complications |
Biopsy |
Treatment
| Lab |
Nutrition |
Patient |
Links | Transplant |
Webrings |
Guestbook |
Awards |
FAQ
|